Covid-19 products face tougher future

We are in the midst of 2023’s first reporting period and many of the world’s largest pharmaceutical companies have presented their figures for the full year 2022. A theme is that products related to the Covid-19 pandemic seem to have reached their peak sales and will face a significantly tougher market going forward. BioStock took a closer look at some of the reports.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/02/covid-19-products-face-tougher-future/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se